Physician profile
Alison Ryan
NPI 1942734504
$2,185.63
in general payments reported to CMS, 2019-2025
27 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $213 · 2023: $478 · 2024: $495 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.83 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.98 | 2022-2025 | |
| Glaxosmithkline, LLC. | $203.69 | 2021-2023 | Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $200.52 | 2023-2024 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $136.46 | 2021 | |
| Janssen Biotech, INC. | $119.04 | 2021-2024 | Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $117.00 | 2024 | Tagrisso |
| Agios Pharmaceuticals, INC. | $108.92 | 2022 | |
| Kite Pharma, INC. | $102.95 | 2021 | |
| Lilly USA, LLC | $85.17 | 2021 | |
| Gilead Sciences, INC. | $77.55 | 2023 | Trodelvy |
| Genzyme Corporation | $69.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $66.36 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $65.69 | 2021 | |
| Pfizer INC. | $54.73 | 2021 | |
| Deciphera Pharmaceuticals INC. | $40.63 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $38.21 | 2021-2022 | |
| Array Biopharma INC | $36.79 | 2025 | Tukysa, Braftovi, Lorbrena |
| Exelixis INC. | $32.50 | 2021 | |
| Seagen INC. | $30.83 | 2021 | |
| Epizyme, INC. | $29.06 | 2021 | |
| Amgen INC. | $22.50 | 2022 | |
| Incyte Corporation | $20.24 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.22 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.61 | 2021 | |
| Taiho Oncology, INC. | $17.39 | 2021 | |
| Myovant Sciences INC. | $15.64 | 2021 | |
| Emd Serono, INC. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.